Readystate Asset Management LP Purchases 161,470 Shares of Replimune Group, Inc. $REPL

Key Points

• Readystate Asset Management increased its Replimune position by 116.6%, purchasing 161,470 shares to own 299,958 shares valued at about $3.3 million. Institutional investors collectively own 92.53% of the company.
• Replimune reported a quarterly loss of $0.72 per share, missing analyst expectations of a $0.69 loss; analysts expect a full-year loss of $2.81 per share.
• The stock opened at $15.04, near its 52-week high of $16.33, while analyst opinion remains a consensus “Moderate Buy” with an average price target of $12.00. Insiders sold shares primarily to cover tax obligations tied to vested equity awards.

Readystate Asset Management LP lifted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 116.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 299,958 shares of the company's stock after buying an additional 161,470 shares during the period. Readystate Asset Management LP owned approximately 0.32% of Replimune Group worth $3,321,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of REPL. Syon Capital LLC acquired a new stake in Replimune Group in the second quarter valued at approximately $247,000. AXQ Capital LP increased its position in shares of Replimune Group by 4.1% during the second quarter. AXQ Capital LP now owns 27,121 shares of the company's stock worth $300,000 after purchasing an additional 1,056 shares in the last quarter. Montanova Capital LLC lifted its holdings in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock valued at $48,595,000 after purchasing an additional 168,000 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Replimune Group during the 2nd quarter valued at $121,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Replimune Group in the 2nd quarter worth $1,035,000. Institutional investors own 92.53% of the company's stock.

Insiders Place Their Bets

In other news, CFO Emily Hill sold 9,256 shares of Replimune Group stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the sale, the chief financial officer owned 215,852 shares in the company, valued at $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the sale, the chief accounting officer directly owned 99,425 shares of the company's stock, valued at $1,289,542.25. This represents a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock valued at $1,038,364 in the last three months. 5.40% of the stock is currently owned by company insiders.

Replimune Group Stock Performance

NASDAQ REPL opened at $15.04 on Monday. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $16.33. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The firm has a market capitalization of $1.41 billion, a P/E ratio of -4.77 and a beta of 0.94. The stock has a 50-day simple moving average of $12.25 and a two-hundred day simple moving average of $8.61.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, equities analysts forecast that Replimune Group, Inc. will post -2.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on REPL shares. Wall Street Zen raised Replimune Group from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 23rd. Piper Sandler raised Replimune Group from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. Weiss Ratings lowered Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective on the stock in a report on Friday, August 7th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $12.00.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source